We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacodynamic Clinical Trial of Cardiovascular Polypill on LDL Cholesterol

This study has been terminated.
(Per sponsor's decision)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01362218
First Posted: May 30, 2011
Last Update Posted: April 24, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Ferrer Internacional S.A.
  Purpose
This study evaluates the effect on LDL cholesterol of the 3 drugs given together in the cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin, and ramipril) as compared to the effect on LDL cholesterol of the reference products (simvastatin, ramipril, acetylsalicylic acid) Approximately 350 subjects will be screened, 266 randomized in order about 238 subjects to finish the study.

Condition Intervention Phase
Elevated LDL Cholesterol Drug: Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril) Drug: Simvastatin, ramipril, acetylsalicylic acid Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Cardiovascular Fixed Combination Pill ASR: Pharmacodynamic Clinical Trial of a Fixed Dose Combination of Acetylsalicylic Acid, Simvastatin, and Ramipril (Cardiovascular Polypill); LDL Cholesterol

Resource links provided by NLM:


Further study details as provided by Ferrer Internacional S.A.:

Primary Outcome Measures:
  • Difference in LDL-cholesterol levels between the basal and the final visit of treatment period. [ Time Frame: Day 56 ]

Secondary Outcome Measures:
  • • Difference in VLDL-cholesterol levels between the basal and the final visit of treatment period. [ Time Frame: Day 56 ]
  • • Difference in HDL-cholesterol levels between the basal and the final visit of treatment period. [ Time Frame: Day 56 ]
  • • Difference in total cholesterol levels between the basal and the final visit of treatment period. [ Time Frame: Day 56 ]
  • • Difference in triglyceride levels between the basal and the final visit of treatment period [ Time Frame: Day 56 ]

Enrollment: 107
Study Start Date: October 2010
Study Completion Date: April 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fixed Dose Combination Pill
A fixed dose combination of acetylsalicylic acid, simvastatin, and ramipril Intervention: Drug: Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril)
Drug: Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril)
A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 8 weeks.
Active Comparator: Simvastatin
Simvastatin given together with the reference drugs ramipril and acetylsalicylic acid
Drug: Simvastatin, ramipril, acetylsalicylic acid
A once daily oral dose of simvastatin, ramipril, acetylsalicylic acid for 8 weeks

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subjects aged ≥18 and <75 years.
  • Previously untreated or not treated with fibrates during the last 6 weeks or with any other lipid lowering drug for the last 4 weeks.
  • LDL-cholesterol ≥130 and ≤220 mg/dL.
  • Systolic blood pressure ≥120 and <160 mmHg and diastolic blood pressure ≥70 and <100 mmHg.
  • Provide written informed consent.

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01362218


Locations
Spain
Hospital Clinic
Barcelona, Spain
Sponsors and Collaborators
Ferrer Internacional S.A.
  More Information

Responsible Party: Ferrer Internacional S.A.
ClinicalTrials.gov Identifier: NCT01362218     History of Changes
Other Study ID Numbers: P-100820-01
First Submitted: May 26, 2011
First Posted: May 30, 2011
Last Update Posted: April 24, 2013
Last Verified: April 2013

Additional relevant MeSH terms:
Simvastatin
Ramipril
Aspirin
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Antihypertensive Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Antipyretics